Innoviva Inc (NASDAQ:INVA)’s share price was up 11.8% during mid-day trading on Friday following a better than expected earnings announcement. The company traded as high as $15.67 and last traded at $15.43. Approximately 2,749,212 shares traded hands during mid-day trading, an increase of 184% from the average daily volume of 967,100 shares. The stock had previously closed at $13.80.

The biotechnology company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The firm had revenue of $69.52 million during the quarter, compared to analysts’ expectations of $67.41 million. During the same period in the prior year, the business earned $0.22 EPS. The company’s revenue for the quarter was up 59.4% compared to the same quarter last year.

A number of research firms have recently issued reports on INVA. Robert W. Baird reiterated a “hold” rating and issued a $13.00 price objective on shares of Innoviva in a report on Tuesday, October 24th. Zacks Investment Research upgraded Innoviva from a “sell” rating to a “hold” rating in a report on Friday. BidaskClub upgraded Innoviva from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Deutsche Bank began coverage on Innoviva in a research note on Monday, November 20th. They issued a “hold” rating and a $13.00 target price for the company. Finally, Cowen set a $16.00 target price on Innoviva and gave the company a “buy” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Innoviva currently has a consensus rating of “Hold” and a consensus price target of $13.83.

In other news, CFO Eric Desparbes sold 15,285 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $13.28, for a total value of $202,984.80. Following the completion of the sale, the chief financial officer now owns 337,027 shares of the company’s stock, valued at approximately $4,475,718.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael W. Aguiar sold 12,022 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $13.13, for a total value of $157,848.86. Following the completion of the sale, the insider now directly owns 980,907 shares of the company’s stock, valued at approximately $12,879,308.91. The disclosure for this sale can be found here. In the last three months, insiders sold 32,522 shares of company stock valued at $429,985. 1.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INVA. Sei Investments Co. raised its position in Innoviva by 33,810.3% during the 3rd quarter. Sei Investments Co. now owns 9,834 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 9,805 shares during the last quarter. Macquarie Group Ltd. bought a new position in Innoviva during the 3rd quarter valued at approximately $144,000. Jane Street Group LLC bought a new position in Innoviva during the 3rd quarter valued at approximately $144,000. Cubist Systematic Strategies LLC raised its position in Innoviva by 37.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,005 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 3,569 shares during the last quarter. Finally, Magnetar Financial LLC bought a new position in Innoviva during the 3rd quarter valued at approximately $182,000. 74.17% of the stock is owned by institutional investors and hedge funds.

The stock has a market capitalization of $1,535.97, a PE ratio of 17.74 and a beta of 2.52. The company has a debt-to-equity ratio of -2.59, a quick ratio of 6.71 and a current ratio of 6.71.

COPYRIGHT VIOLATION WARNING: “Innoviva (INVA) Trading Up 11.8% Following Strong Earnings” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/innoviva-inva-trading-up-11-8-following-strong-earnings.html.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.